TABLE 3.
Pilot HTS with Pfizer's compound platesa
| Plate no. | No. of hits identified
|
||||
|---|---|---|---|---|---|
| 2a replicon system | FMDV2A system | 2a replicon- FMDV2A overlap | 2a replicon system only | FMDV2A system only | |
| 1 | 1 | 16 | 0 | 1 | 16 |
| 2 | 7 | 21 | 5 | 2 | 16 |
| 3 | 0 | 5 | 0 | 0 | 5 |
| 4 | 2 | 11 | 2 | 0 | 9 |
| 5 | 0 | 3 | 0 | 0 | 3 |
| 6 | 0 | 5 | 0 | 0 | 5 |
| 7 | 1 | 10 | 0 | 1 | 10 |
| 8 | 3 | 5 | 2 | 1 | 3 |
| 9 | 16 | 25 | 15 | 1 | 10 |
| 10 | 8 | 8 | 7 | 1 | 1 |
| Total | 38 | 109 | 31 | 7 | 78 |
a
Ten 96-well compound plates were screened, as described in Materials and Methods. Numbers of hits are given for each system separately and for overlapping hits as well as for exclusive hits (2a replicon only and FMDV2A only). FMDV2A, C33J-Y835C-FMDV2A system.